Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
SRPTthis companySarepta Therapeutics, Inc.	$17.41	-3.02×	1.98×	1.03×	-3.85×	-6425.5%	59.9%	-29.9%	-32.5%	-62.5%	-29.0%	-13.6%	0.91×	-0.37×	-67.6×	2.32×	0.0%	3	-0.09	2	C+
ALNYAlnylam Pharmaceuticals, Inc.	$156.13	166.38×	66.01×	14.03×	81.9×	-1017.9%	81.8%	13.5%	8.4%	39.8%	13.7%	0.9%	1.62×	-0.6×	1.99×	2.76×	0.0%	5	3.79	4	A-
CAPRCapricor Therapeutics, Inc.	$9.10	-12.77×	4.39×	0×	-10.7×	-20.2%	0.0%	0.0%	0.0%	-34.4%	-33.4%	-5.4%	0.06×	2.7×	-35.51×	9.01×	0.0%	2	0.16	2	C
DSGNDesign Therapeutics, Inc.	$10.55	-7.69×	2.53×	0×	-7.55×	-97.5%	0.0%	0.0%	0.0%	-32.8%	-37.1%	-10.1%	0.01×	0.22×	0×	17.14×	0.0%	1	26.54	2	C
DYNDyne Therapeutics, Inc.	$18.43	-5.64×	2.58×	0×	-3.74×	-61.0%	0.0%	0.0%	0.0%	-45.9%	-41.0%	-16.1%	0.02×	1.99×	-75.61×	22.25×	0.0%	2	3.6	2	C+
IONSIonis Pharmaceuticals, Inc.	$28.90	-33.24×	25.88×	13.41×	-52.41×	-292.2%	98.3%	-40.5%	-40.4%	-77.9%	-12.0%	-2.5%	5.35×	-7.89×	-4.22×	3.83×	0.0%	2	0.89	1	D+
Peer median	—	-7.69×	4.39×	0×	-7.55×	-97.5%	0.0%	0.0%	0.0%	-34.4%	-33.4%	-5.4%	0.06×	0.22×	-4.22×	9.01×	0.0%	2	3.6	2	—